Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapyCristina Puig-Saus, Alena Gros, Barbara Sennino et al.|Nature|2023Cited by 206
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategiesAlexandra Dreyzin, Nirali N. Shah, Bita Sahaf et al.|Cytotherapy|2025Cited by 1